<DOC>
	<DOCNO>NCT00834418</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 20 mg Leflunomide Tablets TEVA Pharmaceuticals Industries , Ltd. 20 mg ARAVA™ Tablets Aventis Pharmaceuticals , Inc. follow single oral dose ( 1 x 20 mg tablet ) healthy adult subject fasting condition .</brief_summary>
	<brief_title>Leflunomide 20 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>Screening Demographics : All subject select study healthy men woman 18 year age old time dose . The weight range exceed ± 20 % height body frame per Desirable Weights Adults 1983 Metropolitan Height Weight Table . Screening procedure : Each subject complete screening process within 28 day prior dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : 1 . Hematology : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count ; 2 . Clinical Chemistry : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase ; 3 . HIV antibody hepatitis B surface screen ; 4 . Urinalysis : dipstick ; full microscopic examination dipstick positive ; 5 . Urine Drug Screen : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine . 6 . Serum Pregnancy Screen ( female subject ) 7 . Follicle Stimulating Hormone [ FSH ] ( female verify postmenopausal status ) If male must vasectomize ( least 3 month ) If female : 1. postmenopausal least 1 year ; 2. surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . Subjects recent history drug alcohol addiction abuse . Subjects presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Subjects whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Subjects demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen . Subjects demonstrate positive drug abuse screen screen study . Female subject currently breastfeed . Female subject demonstrate positive pregnancy screen . Subjects history allergic response ( ) leflunomide relate drug . Subjects history clinically significant allergy include drug allergy . Subjects clinically significant illness 4 week prior dose ( determined clinical investigator ) . Subjects take drug know induce inhibit hepatic drug metabolism 30 day prior dose . Subjects report donate great 150 mL blood within 30 day prior dose . All subject advise donate blood four week complete study . Subjects donate plasma ( e.g . plasmapheresis ) within 14 day prior dose . All subject advise donate plasma four week complete study . Subjects report receive investigational drug within 30 day prior dose . Subjects report take prescription medication 14 day prior dose , exception postmenopausal woman HRT may continue HRT topical product without systemic absorption . Subjects report intolerance direct venipuncture . Subjects report consume abnormal diet 28 day prior dose . Subjects report take product contain leflunomide within 180 day dose . Subjects report take herbal product within 7 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>